

the required fee, an Information Disclosure Statement, and a Declaration of David Berd, M.D. under 37 C.F.R. §1.132 ("Berd Declaration").

Please amend the above-identified application as follows:

IN THE CLAIMS

Please amend the claims pursuant to 37 C.F.R. §1.121 as follows (see the accompanying "marked up" version pursuant to §1.121):

1. (TwiceAmended) A method for inducing an anti-tumor response in a mammalian patient suffering from a tumor, which method comprises administering to said patient a composition comprising a tumor cell or tumor cell extract with an adjuvant, wherein the tumor cell or tumor cell extract is:

- (i) conjugated to a hapten;
- (ii) of the same tumor type as the patient's tumor;
- (iii) not allogeneic to said patient, and
- (iv) incapable of growing in the body of the patient after injection; and repeating said administration at weekly intervals, wherein the composition, when administered with the adjuvant, elicits an anti-tumor response, and comprises a maximum of 7.5×10^6 cells or cell equivalents extract per dose.

REMARKS

The present amendment is submitted with a Request for Continued Examination of this application. Withdrawal of the finality of the prior Office Action